このアイテムのアクセス数: 521
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
25785826.2021.1928383.pdf | 2.56 MB | Adobe PDF | 見る/開く |
タイトル: | Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort |
著者: | Watanabe, Ryu Hashimoto, Motomu Murata, Koichi Murakami, Kosaku Tanaka, Masao Ohmura, Koichiro Ito, Hiromu Matsuda, Shuichi |
著者名の別形: | 渡部, 龍 橋本, 求 村田, 浩一 村上, 孝作 田中, 真生 大村, 浩一郎 伊藤, 宣 松田, 秀一 |
キーワード: | Difficult-to-treat rheumatoid arthritis disease activity pulmonary involvement rheumatoid arthritis rheumatoid factor |
発行日: | 2022 |
出版者: | Taylor & Francis |
誌名: | Immunological Medicine |
巻: | 45 |
号: | 1 |
開始ページ: | 35 |
終了ページ: | 44 |
抄録: | Difficult-to-treat rheumatoid arthritis (D2T RA) is a multifactorial condition in which disease activity of RA persists despite consecutive treatment with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). To evaluate the prevalence and predictive risk factors of D2T RA in our institution, a single-center, retrospective study was conducted. Medical records of RA patients, who visited our hospital from 2011 to 2020 and had a follow-up of more than 6 months, were retrospectively reviewed. D2T RA was defined as RA with a disease activity score of 28 - erythrocyte sedimentation rate (DAS28-ESR) of 3.2 or higher at the last visit, despite the use of at least two b/tsDMARDs. A logistic regression model was used to identify risk factors. A total of 672 patients were enrolled. The mean age at disease onset was 52.1 years and females were dominant (76.3%). After a mean follow-up of 46.6 months, patients with D2T RA accounted for 7.9% of overall patients. Multivariate analysis identified high rheumatoid factor (RF) levels (≥156.4 IU/mL, odds ratio [OR]: 1.95), DAS28-ESR (OR: 1.24), and coexisting pulmonary disease (OR: 2.03) as predictive risk factors of D2T RA. In conclusion, high RF levels, high DAS28-ESR, and coexisting pulmonary disease at baseline can predict the development of D2T RA. |
著作権等: | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
URI: | http://hdl.handle.net/2433/276207 |
DOI(出版社版): | 10.1080/25785826.2021.1928383 |
PubMed ID: | 34033729 |
出現コレクション: | 学術雑誌掲載論文等 |

このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス